Prognostic impact of the activation status of the Akt/mTOR pathway in synovial sarcoma

Cancer

Volumn 119, Issue 19, 2013, Pages 3504-3513

  Setsu, Nokitaka ^a   Kohashi, Kenichi ^a   Fushimi, Fumiyoshi ^b   Endo, Makoto ^a   Yamamoto, Hidetaka ^a   Takahashi, Yusuke ^a   Yamada, Yuichi ^a   Ishii, Takeaki ^a   Yokoyama, Koichirou ^b   Iwamoto, Yukihide ^a   Oda, Yoshinao ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

Akt; mammalian target of rapamycin; mutation; prognosis; synovial sarcoma

Indexed keywords

CISPLATIN; DOXORUBICIN; IFOSFAMIDE; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE CATALYTIC SUBUNIT ALPHA; PROTEIN KINASE B; S6 KINASE; UNCLASSIFIED DRUG; VINCRISTINE;

ADULT; AKT1 GENE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; EVENT FREE SURVIVAL; FEMALE; GENE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MITOSIS; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; SURVIVAL RATE; SYNOVIAL SARCOMA; TUMOR LOCALIZATION; TUMOR NECROSIS; TUMOR VOLUME; WESTERN BLOTTING;

AKT; MAMMALIAN TARGET OF RAPAMYCIN; MUTATION; PROGNOSIS; SYNOVIAL SARCOMA;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHOPROTEINS; PHOSPHORYLATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEIN S6; SARCOMA, SYNOVIAL; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TOR SERINE-THREONINE KINASES;

EID: 84884908724     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28255     Document Type: Article

References (31)

1. Ruvinsky I, Meyuhas O,. Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. Trends Biochem Sci. 2006; 31: 342-348.
2. West MJ, Stoneley M, Willis AE,. Translational induction of the c-myc oncogene via activation of the FRAP/TOR signalling pathway. Oncogene. 1998; 17: 769-780.
3. Tornkvist M, Natalishvili N, Xie Y, et al. Differential roles of SS18-SSX fusion gene and insulin-like growth factor-1 receptor in synovial sarcoma cell growth. Biochem Biophys Res Commun. 2008; 368: 793-800.
4. Watanabe T, Tsuda M, Tanaka S, et al. Adaptor protein crk induces src-dependent activation of p38 MAPK in regulation of synovial sarcoma cell proliferation. Mol Cancer Res. 2009; 7: 1582-1592.
5. Friedrichs N, Trautmann M, Endl E, et al. Phosphatidylinositol-3′- kinase/AKT signaling is essential in synovial sarcoma. Int J Cancer. 2011; 129: 1564-1575.
6. Hosaka S, Horiuchi K, Yoda M, et al. A novel multi-kinase inhibitor pazopanib suppresses growth of synovial sarcoma cells through inhibition of the PI3K-AKT pathway. J Orthop Res. 2012; 30: 1493-1498.
7. Chawla SP, Staddon AP, Baker LH, et al. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol. 2012; 30: 78-84.
8. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers [serial online]. Science. 2004; 304: 554.
9. Carpten JD, Faber AL, Horn C, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature. 2007; 448: 439-444.
10. \Fisher C, de Bruijn DRH, Geurts van Kessel A,. Synovial sarcoma. In:, Fletcher CD, Unni KK, Mertens FE, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon, France: IARC Press; 2002: 200-204.
11. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC Cancer Staging Manual. 7th ed. St. Louis, MO: Springer; 2010.
12. Setsu N, Yamamoto H, Kohashi K, et al. The Akt/mammalian target of rapamycin pathway is activated and associated with adverse prognosis in soft tissue leiomyosarcomas. Cancer. 2012; 118: 1637-1648.
13. Dobashi Y, Suzuki S, Sato E, Hamada Y, Yanagawa T, Ooi A,. EGFR-dependent and independent activation of Akt/mTOR cascade in bone and soft tissue tumors. Mod Pathol. 2009; 22: 1328-1340.
14. Bozzi F, Ferrari A, Negri T, et al. Molecular characterization of synovial sarcoma in children and adolescents: evidence of Akt activation. Transl Oncol. 2008; 1: 95-101.
15. Tomita Y, Morooka T, Hoshida Y, et al. Prognostic significance of activated AKT expression in soft-tissue sarcoma. Clin Cancer Res. 2006; 12: 3070-3077.
16. Bergh P, Meis-Kindblom JM, Gherlinzoni F, et al. Synovial sarcoma: identification of low and high risk groups. Cancer. 1999; 85: 2596-2607.
17. Trassard M, Le Doussal V, Hacene K, et al. Prognostic factors in localized primary synovial sarcoma: a multicenter study of 128 adult patients. J Clin Oncol. 2001; 19: 525-534.
18. Deshmukh R, Mankin HJ, Singer S,. Synovial sarcoma: the importance of size and location for survival. Clin Orthop Relat Res. 2004; 419: 155-161.
19. Sun Y, Sun B, Wang J, et al. Prognostic implication of SYT-SSX fusion type and clinicopathological parameters for tumor-related death, recurrence, and metastasis in synovial sarcoma. Cancer Sci. 2009; 100: 1018-1025.
20. Takenaka S, Ueda T, Naka N, et al. Prognostic implication of SYT-SSX fusion type in synovial sarcoma: a multi-institutional retrospective analysis in Japan. Oncol Rep. 2008; 19: 467-476.
21. Jiang YP, Ballou LM, Lin RZ,. Rapamycin-insensitive regulation of 4e-BP1 in regenerating rat liver. J Biol Chem. 2001; 276: 10943-10951.
22. Jefferson LS, Kimball SR,. Amino acid regulation of gene expression. J Nutr. 2001; 131: 2460S-2466S; discussion 2486S-2487S.
23. Barretina J, Taylor BS, Banerji S, et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet. 2010; 42: 715-721.
24. Teng HW, Wang HW, Chen WM, et al. Prevalence and prognostic influence of genomic changes of EGFR pathway markers in synovial sarcoma. J Surg Oncol. 2011; 103: 773-781.
25. Thomas DG, Giordano TJ, Sanders D, et al. Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma. Cancer. 2005; 103: 830-838.
26. Sato O, Wada T, Kawai A, et al. Expression of epidermal growth factor receptor, ERBB2 and KIT in adult soft tissue sarcomas: a clinicopathologic study of 281 cases. Cancer. 2005; 103: 1881-1890.
27. Steigen SE, Schaeffer DF, West RB, Nielsen TO,. Expression of insulin-like growth factor 2 in mesenchymal neoplasms. Mod Pathol. 2009; 22: 914-921.
28. Lopez-Guerrero JA, Navarro S, Noguera R, et al. Mutational analysis of the c-KIT AND PDGFRalpha in a series of molecularly well characterized synovial sarcomas. Diagn Mol Pathol. 2005; 14: 134-139.
29. Ho AL, Vasudeva SD, Lae M, et al. PDGF receptor alpha is an alternative mediator of rapamycin-induced Akt activation: implications for combination targeted therapy of synovial sarcoma. Cancer Res. 2012; 72: 4515-4525.
30. van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012; 379: 1879-1886.
31. Schwartz GK, Tap WD, Qin LX, et al. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2013; 14: 371-382.